Esperion Therapeutics Sees FY24 Revenues $225M-$245M, Including $20M In Non-cash Expenses Related To Stock Compensation
Esperion Therapeutics Sees FY24 Revenues $225M-$245M, Including $20M In Non-cash Expenses Related To Stock Compensation
Esperion Therapeutics预计24财年收入为2.25亿至2.45亿美元,其中包括与股票薪酬相关的2000万美元非现金支出
Esperion Therapeutics Sees FY24 Revenues $225M-$245M, Including $20M In Non-cash Expenses Related To Stock Compensation
Esperion Therapeutics预计24财年收入为2.25亿至2.45亿美元,其中包括与股票薪酬相关的2000万美元非现金支出
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。